ABUS icon

Arbutus Biopharma
ABUS

Overview Fund Activity

48 hedge funds and large institutions have $115M invested in Arbutus Biopharma in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
48
Holders Change
-3
Holders Change %
-5.88%
% of All Funds
1.28%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.03%
New
5
Increased
17
Reduced
14
Closed
8
Calls
$880K
Puts
$819K
Net Calls
+$61K
Net Calls Change
+$151K

Top Buyers

1
QF
1
QVT Financial
New York
$55.1M
2
AC
2
Armistice Capital
New York
$4.82M
3
Bank of Montreal
3
Bank of Montreal
Ontario, Canada
$2.96M
4
KPF
4
K2 Principal Fund
Ontario, Canada
$370K
5
Renaissance Technologies
5
Renaissance Technologies
New York
$399K

Top Sellers

1
SM
1
Sabby Management
Florida
$3.02M
2
HM
2
HealthCor Management
New York
$6.88M
3
IGIM
3
I.G. Investment Management
Manitoba, Canada
$0
4
SCM
4
Suffolk Capital Management
New York
$1.08M
5
Millennium Management
5
Millennium Management
New York
$1.64M
Name Holding Trade Value Shares
Change 		Shares
Change %
TC
51
TFS Capital
Pennsylvania
– -$107K -30,860 Closed
SLG
52
Stanley-Laman Group
Pennsylvania
– -$90K -25,722 Closed
DCM
53
Dialectic Capital Management
Connecticut
– -$87K -25,000 Closed
JPMorgan Chase & Co
54
JPMorgan Chase & Co
New York
– -$6K -1,400 Closed
1 2
3